Literature DB >> 12630911

Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).

Joanna R Worley1, Philip B Thompkins, Meng H Lee, Mike Hutton, Paul Soloway, Dylan R Edwards, Gillian Murphy, Vera Knäuper.   

Abstract

Fundamental cellular processes including angiogenesis and cell migration require a proteolytic cascade driven by interactions of membrane-type matrix metalloproteinase 1 (MT1-MMP) and progelatinase A (proMMP-2) that are dependent on the presence of tissue inhibitor of metalloproteinases 2 (TIMP-2). There are unique interactions between TIMP-2 and MT1-MMP, which we have previously defined, and here we identify TIMP-2 sequence motifs specific for proMMP-2 binding in the context of its activation by MT1-MMP. A TIMP-2 mutant encoding the C-terminal domain of TIMP-4 showed loss of proMMP-2 activation, indicating that the C-terminal domain of TIMP-2 is important in establishing the trimolecular complex between MT1-MMP, TIMP-2 and proMMP-2. This was confirmed by analysis of a TIMP-4 mutant encoding the C-terminal domain of TIMP-2, which formed a trimolecular complex and promoted proMMP-2 processing to the intermediate form. Mutants encoding TIMP-4 from Cys(1) to Leu(185) and partial tail sequence of TIMP-2 showed some gain of activating capability relative to TIMP-4. The identified residues were subsequently mutated in TIMP-2 (E(192)-D(193) to I(192)-Q(193)) and this inhibitor showed a significantly reduced ability to facilitate proMMP-2 processing by MT1-MMP. Furthermore, the tail-deletion mutant Delta(186-194)TIMP-2 was completely incapable of promoting proMMP-2 activation by MT1-MMP. Thus the C-terminal tail residues of TIMP-2 are important determinants for stable trimolecular complex formation between TIMP-2, proMMP-2 and MT1-MMP and play an important role in MT1-MMP-mediated processing to the intermediate and final active forms of MMP-2 at the cell surface.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12630911      PMCID: PMC1223438          DOI: 10.1042/BJ20021573

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

2.  Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP.

Authors:  S Hernandez-Barrantes; Y Shimura; P D Soloway; Q A Sang; R Fridman
Journal:  Biochem Biophys Res Commun       Date:  2001-02-16       Impact factor: 3.575

Review 3.  Tissue inhibitors of metalloproteinases: evolution, structure and function.

Authors:  K Brew; D Dinakarpandian; H Nagase
Journal:  Biochim Biophys Acta       Date:  2000-03-07

4.  Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.

Authors:  H F Bigg; C J Morrison; G S Butler; M A Bogoyevitch; Z Wang; P D Soloway; C M Overall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

5.  TIMP-2 is required for efficient activation of proMMP-2 in vivo.

Authors:  Z Wang; R Juttermann; P D Soloway
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

6.  Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(Timp-2) gene alters proMMP-2 activation.

Authors:  J J Caterina; S Yamada; N C Caterina; G Longenecker; K Holmbäck; J Shi; A E Yermovsky; J A Engler; H Birkedal-Hansen
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

7.  Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2.

Authors:  M Toth; M M Bernardo; D C Gervasi; P D Soloway; Z Wang; H F Bigg; C M Overall; Y A DeClerck; H Tschesche; M L Cher; S Brown; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

Review 8.  Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy.

Authors:  A H Baker; M Ahonen; V M Kähäri
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

9.  Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway.

Authors:  C J Morrison; G S Butler; H F Bigg; C R Roberts; P D Soloway; C M Overall
Journal:  J Biol Chem       Date:  2001-10-02       Impact factor: 5.157

10.  Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation.

Authors:  S Hernandez-Barrantes; M Toth; M M Bernardo; M Yurkova; D C Gervasi; Y Raz; Q A Sang; R Fridman
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

View more
  17 in total

1.  Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes.

Authors:  Roberto Romero; Digna R Velez Edwards; Juan Pedro Kusanovic; Sonia S Hassan; Shali Mazaki-Tovi; Edi Vaisbuch; Chong Jai Kim; Tinnakorn Chaiworapongsa; Brad D Pearce; Lara A Friel; Jacquelaine Bartlett; Madan Kumar Anant; Benjamin A Salisbury; Gerald F Vovis; Min Seob Lee; Ricardo Gomez; Ernesto Behnke; Enrique Oyarzun; Gerard Tromp; Scott M Williams; Ramkumar Menon
Journal:  Am J Obstet Gynecol       Date:  2010-05       Impact factor: 8.661

2.  Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).

Authors:  Xiaoping Xu; Margarita Mikhailova; Zhihua Chen; Sanjay Pal; Trista K Robichaud; Eileen M Lafer; Sam Baber; Bjorn Steffensen
Journal:  Matrix Biol       Date:  2011-08-04       Impact factor: 11.583

3.  Filamin A controls matrix metalloproteinase activity and regulates cell invasion in human fibrosarcoma cells.

Authors:  Massimiliano Baldassarre; Ziba Razinia; Nina N Brahme; Roberto Buccione; David A Calderwood
Journal:  J Cell Sci       Date:  2012-05-17       Impact factor: 5.285

Review 4.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

Review 5.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

Review 6.  Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors.

Authors:  Francis G Spinale; Francisco Villarreal
Journal:  Biochem Pharmacol       Date:  2014-04-26       Impact factor: 5.858

7.  The α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells.

Authors:  Aaron M Dom; Adam W Buckley; Kathleen C Brown; Richard D Egleton; Aileen J Marcelo; Nancy A Proper; Donald E Weller; Yashoni H Shah; Jamie K Lau; Piyali Dasgupta
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-22       Impact factor: 4.799

8.  Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.

Authors:  Valéria A Gomes; Carolina S Vieira; Anna L Jacob-Ferreira; Vanessa A Belo; Gustavo M Soares; Janaína B F Fernandes; Rui A Ferriani; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2011-03-25       Impact factor: 3.396

9.  Endothelial cell microparticles act as centers of matrix metalloproteinsase-2 (MMP-2) activation and vascular matrix remodeling.

Authors:  Thomas P Lozito; Rocky S Tuan
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

10.  Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2.

Authors:  Renu A Kowluru; Mamta Kanwar
Journal:  Free Radic Biol Med       Date:  2009-04-05       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.